📽️Watch @DrMarthaGulati provide her takeaways from the DECAF trial presented at #AHA25   What will she tell her patients with #Afib about drinking☕?

📽️Ann Marie Navar, MD, PhD, explains the key messages of the CORALreef Lipids trial showing an oral PCKS9 inhibitor lowered lipids just as much as injectable forms #AHA25 @Merck

🔥Fresh perspective from Keith Ferdinand, MD, on the VESALIUS-CV trial, which find the PCSK9 inhibitor evolocumab cut risk for a first major cardiovascular event by 25% vs. placebo   #AHA25

New data from SURPASS-CVOT presented at #AHA25 showed #tirzepatide conferred similar benefit for many CV outcomes to dulaglutide in patients with #diabetes regardless of whether they also had HF. @HeartNews @AHAMeetings @EndocrineToday https://t.co/H4fzAVhbCj

⚠️At #LM2025 Koushik Reddy, MD, FACC, FACLM, DipABLM, discussed the “carrots” of lifestyle medicine intensification and the ways they’ve been worked into his clinical workflow. @ACLifeMed @GoHealio https://t.co/3Z3gJO7iyw

🔬 Are Biosimilars Safe and Effective? Here’s What the Data Says: https://t.co/BjruVSV2b7 #Biosimilars #PatientSafety #ClinicalTrials

❤️New from #LM2025❤️   To address the growing burden of CV mortality, one interventional cardiologist said to “flip the script,” by addressing #lifestylemedicine as a foundation of health care and not only managing disease. @ACLifeMed @GoHealio https://t.co/3Z3gJO7iyw

On the move? 🚗 So are we. CME made easy, anywhere. Tap In: https://t.co/fMtRrkPoK7 #HealioCME #FreeCME #MedicalEducation

“These [data] are by far the strongest evidence that complete revascularization improves important clinical outcomes in patients with acute MI and multivessel coronary disease,” @ShamirMehta said at #AHA25. @HeartNews @AHAMeetings https://t.co/cq42lHw4xI

“There is a need for increased awareness and education, both for patients as well as the clinicians who care for these patients in their postpartum period,” @meganmclmd of @UCSFCardiology said at #AHA25 @AHAMeetings @HealioWomen @EndocrineToday https://t.co/6GuI757uGZ

“These data ... establish complete revascularization for patients with acute MI as one of the few clinical indications where a [percutaneous coronary intervention]-based strategy reduces cardiovascular and all-cause death,” @ShamirMehta said at #AHA25. https://t.co/cq42lHw4xI

❤️Update from #AHA25 ❤️ A new study identified significant disparities in postpartum care after a hypertensive disorder of pregnancy in the United States @AHAMeetings @AHAScience @HealioWomen @EndocrineToday https://t.co/6GuI757uGZ

In a meta-analysis of individual patient data from six trials presented at #AHA25, complete revascularization reduced death and new MI in patients with acute MI and multiple lesions vs. culprit-only revascularization. @ShamirMehta @HeartNews @AHAMeetings https://t.co/cq42lHw4xI

🗣️ “Baxdrostat 2 mg per day … resulted in substantial, I would say, remarkable, reductions in 24-hour ambulatory systolic pressure at 12 weeks in patients with resistant hypertension,” Bryan Williams, OBE, MD, FMedSci, of @TheBHF said at #AHA25 https://t.co/VyPZghKtlY

🔑 takeaways: ✅ In the the OCEANIC-STROKE trial, asundexian met the primary efficacy and safety endpoints 🩸 The drug did not raise major bleeding risk vs. placebo. ⚠️This is the first successful phase 3 trial of a factor XIa inhibitor. https://t.co/B4DcA8yD4m

🗣️ “By involving local community members, this study was found affordable and a simple way to help everyone lower their blood pressure overall,” Jun Cai, MD, PhD, professor at Beijing Anzhen Hospital, said at #AHA25 https://t.co/1QRUraeGrH @HeartNews @AHAMeetings

Bax24 🔑 takeaways: 🩺Baxdrostat reduced 24-hour BP in patients with resistant hypertension already on maximally tolerated antihypertensive therapy ❗The number needed to treat to achieve BP control was 2️⃣ https://t.co/VyPZghKtlY @AHAMeetings @AHAScience #cardiology

❤️Update from #AHA25 ❤️ Once-daily baxdrostat, when added on top of maximally tolerated antihypertensive therapy, significantly reduced 24-hour BP in people with resistant hypertension. https://t.co/VyPZghKtlY @TheBHF @AHAMeetings @AHAScience #cardiology

🗣️ Dr. Miguel Debono of @SheffieldHosp discusses how metyrapone may provide a pharmacotherapy option for treating some patients with mild autonomous cortisol secretion. Read more ⬇️ @CardiologyToday https://t.co/Qftk4lYJ9d

🚨The positive topline results from OCEANIC-STROKE, the first successful phase 3 study of a factor XIa inhibitor, were announced today🚨 Read more here: https://t.co/B4DcA8yD4m @HealioNeurology #cardiology